NEW FUNDING OPPORTUNITY!
TUCSON, Ariz, January 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. These BRIDGe awards are designed to support academic researchers in traversing the drug development valley of death by providing funding and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.
Maaike Everts, Ph.D., Executive Director of C-Path’s TRxA, expressed her enthusiasm for this next cycle of awards, stating, “The impactful progress in our currently funded projects serves as a testament to the power of collaboration in drug discovery and development; we look forward to identifying the exceptional projects that will emerge from this cycle and, together, shaping the next generation of life changing medicines.”
As a nonprofit drug accelerator, TRxA provides the following for principal investigators who are selected to receive a BRIDGe award:
- Tactical and strategic drug discovery and development expertise, including regulatory science considerations.
- Resources and hands-on guidance, working closely with academic researchers to develop comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies to invest in clinical trials.
- Engagement of contract research organizations (CRO) to perform critical discovery phase experiments and/or validate academic studies.
More information about this funding opportunity is available in TRxA’s Guidance Document for Applicants. Also, be sure to register for the 2024 TRxA Funding Opportunities webinar at 10 a.m. ET, Tuesday, January 30. Content will include an overview of the types of projects TRxA funds, eligibility criteria for TRxA awards, and details about how to apply before the first submission deadline of March 31, 2024. The webinar will conclude with a live Q&A.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling $19,436,549, and 46% funded by non-government source(s), totaling $16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
About C-Path’s Translational Therapeutics Accelerator (TRxA)
Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) is a not-for-profit global drug accelerator focused on supporting academic scientists in advancing novel therapeutics from university-based labs to drug development pipelines of pharmaceutical companies and, ultimately, the clinic. As a neutral convener of patient groups, academia, pharmaceutical companies and regulatory agencies, C-Path brings a breadth of scientific and drug development planning not available in other accelerator programs. TRxA is uniquely situated to leverage the expertise available through C-Path’s >20 disease-based consortia, as well as regulatory expertise and project management, to empower academic investigators to succeed in bringing safe and effective treatments to patients. For more information, visit c-path.org/trxa or email email@example.com.